Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ocular Therapeutix (OCUL) PT Raised to $30 at JMP Securities
November 9, 2021 6:26 AM ESTJMP Securities analyst Jonathan Wolleben raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $30.00 (from $27.00) while maintaining a Market Outperform rating.... More
Ocular Therapeutix (OCUL) Tops Q3 EPS by 3c
November 8, 2021 4:34 PM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.15 million versus the consensus estimate of $12.45 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... MoreOcular Therapeutix (OCUL) Announces Update from Centers for Medicare and Medicaid Services for Reimbursement of DEXTENZA
November 5, 2021 9:01 AM EDTOcular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022.
The OPPS final rule confirms that DEXTENZA will continue to be... More
